PubMed

Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004.

Senkus-Konefka E, Jassem J.

Breast Cancer Res. 2004;6(4):148-52. Epub 2004 May 18.PMID: 15217485 [PubMed - indexed for MEDLINE]Related articlesFree article

Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.

Jahanzeb M.

Clin Ther. 2007 Aug;29(8):1535-47. Review.PMID: 17919537 [PubMed - indexed for MEDLINE]Related articles

Extended adjuvant therapy with letrozole: reducing the risk of recurrence.

Dixon JM.

Expert Rev Anticancer Ther. 2006 Jun;6(6):849-59. Review.PMID: 16761928 [PubMed - indexed for MEDLINE]Related articles

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.PMID: 17610808 [PubMed - indexed for MEDLINE]Related articlesFree article

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.PMID: 17993229 [PubMed - indexed for MEDLINE]Related articles

The evolving role of aromatase inhibitors in adjuvant breast cancer therapy.

Henderson IC, Piccart-Gebhart MJ.

Clin Breast Cancer. 2005 Aug;6(3):206-15. Review.PMID: 16137430 [PubMed - indexed for MEDLINE]Related articles

The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.

Mouridsen HT, Robert NJ.

Eur J Cancer. 2005 Aug;41(12):1678-89. Epub 2004 Nov 25. Review.PMID: 16098456 [PubMed - indexed for MEDLINE]Related articles

Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?

Kaufmann M, Rody A.

Eur J Obstet Gynecol Reprod Biol. 2006 Jun 1;126(2):146-54. Epub 2006 Apr 18. Review.PMID: 16621229 [PubMed - indexed for MEDLINE]Related articles

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.PMID: 17430582 [PubMed - indexed for MEDLINE]Related articlesFree article

Aromatase inhibitors for the treatment and prevention of breast cancer.

Kalidas M, Brown P.

Clin Breast Cancer. 2005 Apr;6(1):27-37. Review.PMID: 15899070 [PubMed - indexed for MEDLINE]Related articles

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Punglia RS, Burstein HJ, Winer EP, Weeks JC.

J Natl Cancer Inst. 2008 May 7;100(9):642-8. Epub 2008 Apr 29.PMID: 18445827 [PubMed - indexed for MEDLINE]Related articlesFree article

Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.

Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R; European Organisation for Research and Treatment of Cancer Breast Group; Scottish Breast Cancer Trials Group.

Eur J Cancer. 2007 Jan;43(2):331-40. Epub 2006 Nov 28.PMID: 17134892 [PubMed - indexed for MEDLINE]Related articles

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.

J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226. PMID: 18073378 [PubMed - indexed for MEDLINE]Related articlesFree article

Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.

Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ.

J Clin Oncol. 2005 Aug 1;23(22):5178-87. Epub 2005 Jul 5.PMID: 15998905 [PubMed - indexed for MEDLINE]Related articles

Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.

Berry J.

Clin Ther. 2005 Nov;27(11):1671-84. Review.PMID: 16368441 [PubMed - indexed for MEDLINE]Related articles

Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer.

Kudachadkar R, O'Regan RM.

CA Cancer J Clin. 2005 May-Jun;55(3):145-63. Review.PMID: 15890638 [PubMed - indexed for MEDLINE]Related articlesFree article

Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen.

Booth CM, Pater JL, Goss PE.

Cancer. 2007 May 1;109(9):1927-8; author reply 1928. No abstract available. PMID: 17354227 [PubMed - indexed for MEDLINE]Related articlesFree article

The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.

Pennery E.

Eur J Oncol Nurs. 2008 Jul;12(3):233-43. Epub 2008 Mar 26. Review.PMID: 18372213 [PubMed - indexed for MEDLINE]Related articles

Anastrozole.

Cuzick J.

Drugs Today (Barc). 2005 Apr;41(4):227-39. Review.PMID: 16034487 [PubMed - indexed for MEDLINE]Related articles

The prevention, detection, and management of breast cancer.

Houssami N, Cuzick J, Dixon JM.

Med J Aust. 2006 Mar 6;184(5):230-4. Review.PMID: 16515434 [PubMed - indexed for MEDLINE]Related articlesFree article